Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bin Fan

Showing results (551-560 of 569) with videos related to

Pageof 57
Sort By:
Molecular Cancer Therapeutics|April 22, 2024
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid TumorsBertha L Rodriguez, Jiawei Huang, Laura Gibson, et al.
Journal of Hepatology|February 27, 2022
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinomaChuan-Yuan Wei, Meng-Xuan Zhu, Peng-Fei Zhang, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Journal of Medicinal Chemistry|December 18, 2009
Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindoleTiansheng Wang, John P Duffy, Jian Wang, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|October 4, 2017
Novel protein therapeutic joint retention strategy based on collagen-binding AvimersJoanne T Hulme, Warren N D'Souza, Helen J McBride, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Theranostics|June 3, 2020
Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational studyPeng Peng Xu, Rong Hua Tian, Song Luo, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Pageof 57

Showing results (551-560 of 569) with videos related to

Sort By:
Pageof 57
Molecular Cancer Therapeutics|April 22, 2024
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid TumorsBertha L Rodriguez, Jiawei Huang, Laura Gibson, et al.
Journal of Hepatology|February 27, 2022
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinomaChuan-Yuan Wei, Meng-Xuan Zhu, Peng-Fei Zhang, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Journal of Medicinal Chemistry|December 18, 2009
Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindoleTiansheng Wang, John P Duffy, Jian Wang, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|October 4, 2017
Novel protein therapeutic joint retention strategy based on collagen-binding AvimersJoanne T Hulme, Warren N D'Souza, Helen J McBride, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Theranostics|June 3, 2020
Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational studyPeng Peng Xu, Rong Hua Tian, Song Luo, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Pageof 57